The Vox Markets Podcast / Neil Clark, Chief Executive Officer of Destiny Pharma #DEST provides updates on the Phase 2b clinical study of their lead asset XF-73

View our embed guidelines

Sorry, your browser isn't supported.

We recommend upgrading to the latest Chrome, Firefox, Safari, or Edge.

You can visit our support center if you're having problems.